ES3018557T3 - Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona - Google Patents

Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona Download PDF

Info

Publication number
ES3018557T3
ES3018557T3 ES16704896T ES16704896T ES3018557T3 ES 3018557 T3 ES3018557 T3 ES 3018557T3 ES 16704896 T ES16704896 T ES 16704896T ES 16704896 T ES16704896 T ES 16704896T ES 3018557 T3 ES3018557 T3 ES 3018557T3
Authority
ES
Spain
Prior art keywords
rpl554
salt
salts
acid
ethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16704896T
Other languages
English (en)
Spanish (es)
Inventor
Peter Lionel Spargo
Edward James French
Julian Scott Northen
John Mykytiuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52781414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3018557(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Application granted granted Critical
Publication of ES3018557T3 publication Critical patent/ES3018557T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
ES16704896T 2015-02-11 2016-02-10 Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona Active ES3018557T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502260A GB201502260D0 (en) 2015-02-11 2015-02-11 Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
PCT/GB2016/050313 WO2016128742A1 (en) 2015-02-11 2016-02-10 Salt of a pyrimido[6,1-a]isoquinolin-4-one compound

Publications (1)

Publication Number Publication Date
ES3018557T3 true ES3018557T3 (es) 2025-05-16

Family

ID=52781414

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16704896T Active ES3018557T3 (es) 2015-02-11 2016-02-10 Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona

Country Status (13)

Country Link
US (2) US10463665B2 (enExample)
EP (2) EP3256472B1 (enExample)
JP (2) JP7089366B2 (enExample)
CN (2) CN113105453A (enExample)
AU (2) AU2016217674B2 (enExample)
CA (1) CA2974605C (enExample)
ES (1) ES3018557T3 (enExample)
GB (1) GB201502260D0 (enExample)
IL (1) IL253595B (enExample)
MX (1) MX382019B (enExample)
PT (1) PT3256472T (enExample)
WO (1) WO2016128742A1 (enExample)
ZA (1) ZA201705112B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10864213B2 (en) 2014-05-12 2020-12-15 Verona Pharma Plc Treatment
MX2017003102A (es) 2014-09-15 2017-06-14 Verona Pharma Plc Formulacion para inhalacion liquida que comprende rpl554.
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) * 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
JP7712276B2 (ja) * 2020-01-15 2025-07-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 三環式ｐｄｅ３／ｐｄｅ４二重阻害剤化合物の医薬組成物
CA3176481A1 (en) * 2020-04-22 2021-10-28 Marjoh NAUTA Coronavirus vaccine
WO2023076205A1 (en) 2021-10-29 2023-05-04 Teva Pharmaceuticals International Gmbh Solid state forms of ensifentrine and process for preparation thereof
TW202325301A (zh) * 2021-12-14 2023-07-01 大陸商海思科醫藥集團股份有限公司 三環稠雜環類pde3/4雙重抑制及其用途
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
JP2025527317A (ja) * 2022-08-08 2025-08-20 ヴェローナ ファーマ ピーエルシー 中等度の慢性閉塞性肺疾患（ｃｏｐｄ）の治療のためのエンシフェントリン（ｒｐｌ－５５４）
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
WO2025176871A1 (en) 2024-02-23 2025-08-28 Inke, S.A. Process for preparing pyrimido[6,1-a]isoquinoline-4-ones
WO2026003867A1 (en) * 2024-06-24 2026-01-02 Neuland Laboratories Limited An improved process for the preparation of ensifentrine and its purification thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6284A1 (en) 1983-05-05 1985-10-30 Hoffmann La Roche Novel pyrimidone derivatives
DE3816995A1 (de) 1988-05-19 1989-11-23 Hoechst Ag Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen
ES2208310T3 (es) 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
US20030235631A1 (en) * 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
DE602005027866D1 (de) * 2004-09-08 2011-06-16 Nycomed Gmbh 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4-inhibitoren
AU2008316284A1 (en) 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
EP2558101A4 (en) 2010-04-15 2013-09-18 Univ Mcgill TOPICAL TREATMENTS OF PAIN
CA2807082C (en) * 2010-08-09 2017-07-25 Verona Pharma Plc Crystalline form of pyrimido[6,1-a]isoquinolin-4-one compound
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
JP6560986B2 (ja) * 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
US10864213B2 (en) 2014-05-12 2020-12-15 Verona Pharma Plc Treatment
MX2017003102A (es) 2014-09-15 2017-06-14 Verona Pharma Plc Formulacion para inhalacion liquida que comprende rpl554.
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
WO2023076205A1 (en) 2021-10-29 2023-05-04 Teva Pharmaceuticals International Gmbh Solid state forms of ensifentrine and process for preparation thereof

Also Published As

Publication number Publication date
CA2974605A1 (en) 2016-08-18
US10463665B2 (en) 2019-11-05
AU2016217674A1 (en) 2017-08-10
CN113105453A (zh) 2021-07-13
US20200016158A1 (en) 2020-01-16
MX2017010195A (es) 2017-11-17
EP4461358A3 (en) 2025-01-15
CN107406446B (zh) 2021-12-28
IL253595A0 (en) 2017-09-28
US11491155B2 (en) 2022-11-08
AU2016217674B2 (en) 2020-04-30
ZA201705112B (en) 2022-05-25
NZ733926A (en) 2023-10-27
JP7110303B2 (ja) 2022-08-01
MX382019B (es) 2025-03-13
EP3256472B1 (en) 2025-03-19
GB201502260D0 (en) 2015-04-01
JP7089366B2 (ja) 2022-06-22
PT3256472T (pt) 2025-04-11
IL253595B (en) 2021-04-29
EP4461358A2 (en) 2024-11-13
JP2018505192A (ja) 2018-02-22
US20180021337A1 (en) 2018-01-25
AU2020205281A1 (en) 2020-08-06
JP2021046405A (ja) 2021-03-25
AU2020205281B2 (en) 2021-07-15
EP3256472A1 (en) 2017-12-20
CA2974605C (en) 2024-02-13
WO2016128742A1 (en) 2016-08-18
CN107406446A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
ES3018557T3 (es) Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona
ES3033142T3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
ES2943109T3 (es) Reducción del tamaño de las partículas de un compuesto antimuscarínico
ES2814336T3 (es) Partículas de agregado
ES2970571T3 (es) Composición farmacéutica líquida que comprende ensifentrina y glicopirrolato
ES2396471T3 (es) Procedimiento para reducir la tendencia de una sal de glicopirronio a agregarse durante el almacenamiento
Ali et al. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote
ES2797073T3 (es) Partículas de inhalación que comprenden una combinación de un anticolinérgico, un corticoesteroide y un beta-adrenérgico
ES2793905T3 (es) Formulación que comprende glicopirrolato, método y aparato
ES2726831T3 (es) Partículas inhalables que comprenden tiotropio e indacaterol
US20100210611A1 (en) Combination therapy
Akdag et al. Formulation and characterization of mometasone furoate and formoterol fumarate containing dry powder inhaler by spray drying and homogenization methods
ES2971768T3 (es) Composición farmacéutica que contiene budesonida y formoterol
US20240033218A1 (en) Dihydroergotamine dry powder formulations and methods of use
NZ733926B2 (en) Salt of a pyrimido[6,1-a]isoquinolin-4-one compound
WO2006076222A2 (en) Pharmaceutical formulations
ES2805434T3 (es) Procedimiento de estabilización de tamaño de partícula
Carvalho Improved inhalation therapies of brittle powders
ES2935112T3 (es) Preparación de partículas micronizadas de un compuesto antimuscarínico mediante cavitación hidrodinámica
BR112016026460B1 (pt) Micropartículas de múltiplos componentes, seu processo de preparação, formulações farmacêuticas e inaladores